Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Supernus ...

Supernus Pharmaceuticals beat analysts’ revenue expectations by 12.2% last quarter, reporting revenues of $174.2 million, up 6% year on year. It was a very strong quarter for the company, ...

Supernus is pulling back after its strong post Q3, 2022 run. See why SUPN's Q4 earnings should be particularly interesting for shareholders.

Supernus continues to grow revenue and earnings and currently has no debt. SPN-810 and SPN-812 are progressing and will have Phase 3 results in about a year.

Supernus Pharmaceuticals Inc., a Rockville-based pharmaceutical company focused on products for the treatment of central nervous system diseases, reported ...

Supernus Pharmaceuticals (SUPN) reported $149.82 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 4.3%. EPS of $0.42 for the same period compares to ...

Supernus Pharmaceuticals sued Indian generic drugmaker Zydus Cadila and its U.S. subsidiary in Manhattan federal court on Friday for allegedly infringing 10 patents with its proposed generic of ...

Supernus reported preliminary data in 2018 showing that the drug met the study’s goal. Last December, Supernus also announced positive results from a Phase 3 study testing its ADHD drug in adults.

Supernus Pharmaceuticals Inc said on Monday it would buy Adamas Pharmaceuticals Inc for about $400 million, to expand its roster of treatments for Parkinson's disease and reduce reliance on its ...

Deal adds Zurzuvae to Supernus' portfolio. Sage Therapeutics accepts $795M buyout from Supernus Pharmaceuticals, surpassing Biogen's offer. Washington Business Journal ...

Supernus Pharmaceuticals is up 1.8% during the same time and is heading into earnings with an average analyst price target of $38.80 (compared to the current share price of $32.84).